Surgery offers multiple long-term benefits when compared to a more interventional approach, though it is still associated with certain risks of its own. In the end, researchers agree, the decision is one that should involve input from surgeons, cardiologists and others.

Bioprosthetic valves are being used more and more for aortic valve replacement, but mechanical valves appear to provide better long-term outcomes for patients 60 and younger. The new study, based on data from nearly 110,000 patients, was presented at STS 2025 and published in the Journal of the American College of Cardiology.

Cardiologists believe this is the first time this exact complication has been reported. Even patients who present with no known risk factors, they said, should receive regular follow-up care to ensure such incidents do not go untreated. 

In addition, researchers noted, five-year mortality was inferior for patients on Medicaid when compared to patients with any other type of insurance. 

When Larry Ellison talks about healthcare AI, people invest. At least, that’s what happened after the Oracle chairman enthused over AI’s potential to cook up vaccines for cancer. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Meril Life Sciences has been manufacturing its Myval heart valves for years. The devices are approved and available in both India and Europe, but they have not been approved by the FDA.